RICHMOND, Calif., April 8, 2019 /PRNewswire/ -- Sangamo
Therapeutics, Inc. (Nasdaq: SGMO) today announced the
completion of its previously announced underwritten public offering
of 12,650,000 shares of its common stock at a price to the public
of $11.50 per share, including 1,650,000 shares sold
pursuant to the exercise in full of the underwriters' option to
purchase additional shares. All of the shares were sold by Sangamo.
Including the option exercise, the aggregate gross proceeds to
Sangamo from the offering, before deducting the underwriting
discounts and commissions and offering expenses, were
approximately $145.5 million.
Sangamo anticipates using the net proceeds from the offering for
working capital and other general corporate purposes, including
support for its own and its partnered gene therapy, genome editing,
cell therapy and gene regulation product candidates and research
programs, its manufacturing facilities and other business
development activities.
Cowen and Company, LLC, Wells Fargo Securities, LLC and Barclays
Capital Inc. acted as joint book-running managers for the
offering.
A registration statement relating to the shares was previously
filed with and became effective by rule of the Securities and
Exchange Commission. The offering was made solely by means of a
prospectus. A final prospectus supplement and accompanying
prospectus relating to the offering has been filed with
the Securities and Exchange Commission and is available
on the Securities and Exchange Commission's website
located at http://www.sec.gov. A copy of the final prospectus
supplement and accompanying prospectus relating to the offering may
be obtained from Cowen and Company, LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631)
274-2806; or from Wells Fargo Securities, LLC, Attention: Equity
Syndicate Department, 375 Park Avenue, New York, NY 10152, or by telephone at (800)
326-5897, or email at cmclientsupport@wellsfargo.com; or from
Barclays Capital Inc., c/o Broadridge Financial Solutions, Attn:
Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888)
603-5847, or by email at barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating
ground-breaking science into genomic medicines with the potential
to transform patients' lives using gene therapy, ex-vivo
gene-edited cell therapy, in vivo genome editing, and gene
regulation.
Forward Looking Statements
This press release contains forward-looking statements regarding
Sangamo's current expectations. These forward-looking statements
include, without limitation, references to Sangamo's anticipated
use of proceeds from the offering. These statements are not
guarantees of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, factors that result in changes to the Company's
anticipated use of proceeds. These and other risks and
uncertainties are described more fully in the section captioned
"Risk Factors" in the final prospectus supplement related to the
public offering that has been filed with the Securities and
Exchange Commission as well as Sangamo's Annual Report on Form
10-K for the year ended December 31,
2018 filed with the Securities and Exchange Commission on
March 1, 2019. Forward-looking
statements contained in this announcement are made as of this date,
and Sangamo undertakes no duty to update such information except as
required under applicable law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-completion-of-public-offering-of-common-stock-and-exercise-in-full-of-underwriters-option-to-purchase-additional-shares-300826371.html
SOURCE Sangamo Therapeutics, Inc.